| |
NewswireToday - /newswire/ -
Basel, Switzerland, 01/10/2008 - Genedata, a leading provider of in silico solutions for drug discovery, today announced a multi-year contract extension for the Genedata Screener® lead discovery product suite with Nycomed, a global manufacturer of innovative pharmaceuticals.
|
| |
Taking a trusted collaboration to the next level, Genedata will create a global scientific computing infrastructure for the lead discovery and drug research programs at Nycomed sites worldwide.
Independent of instrumentation, technology, volume or location, Genedata Screener will enable the interdisciplinary teams at all sites to rapidly capture, visualize, analyze and manage large volumes of assay data. Low to ultra-high throughput screens, single-point assays or complex high content screens will all benefit from Screener's high performance and flexibility. The effective combination of these findings with data from other corporate sources, accessible through Screener's powerful and easy to use viewing tools, will provide Nycomed scientists with the range of information they need to enhance their lead finding processes – anywhere on the globe.
Dr. Werner Stürmer, Head of HTS at Nycomed, explained, “Genedata Screener not only improves the efficiency and quality of our screening campaigns, but also has a catalytic impact on our global information network – increasing the number of users and promoting accurate and timely decisions across departments and countries.“
Dr. Stephan Heyse, Head of the Genedata Screener Business Unit, added, “Our high performance and advanced quality control capabilities together with the established professional services and low maintenance cost will help to ease time constraints and to streamline communication, while generating high-quality results.”
|
communications[.]genedata.com 
